Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (401-410 of 785) with videos related to

Pageof 79
Sort By:
Kidney International Reports|August 4, 2023
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)William G Herrington, Charlie Harper, Natalie Staplin, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|July 2, 2011
Tei index in fabry diseaseMarkus Niemann, Frank Breunig, Meinrad Beer, et al.
Advances in Therapy|May 28, 2025
Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative ReviewChristoph Wanner, Ming-Hui Zhao, Alpesh N Amin, et al.
Open Heart|July 19, 2018
Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry diseaseDan Liu, Daniel Oder, Tim Salinger, et al.
Molecular Genetics and Metabolism|May 23, 2018
The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of expertsMarco Spada, Ralf Baron, Perry M Elliott, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 3, 2016
Performance of hemodialysis with novel medium cut-off dialyzersAlexander H Kirsch, Raphael Lyko, Lars-Göran Nilsson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 9, 2021
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME TrialOdette S Reifsnider, Anuraag R Kansal, Christoph Wanner, et al.
Eclinicalmedicine|January 10, 2022
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomesPiero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 16, 2011
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysisWinfried März, Bernd Genser, Christiane Drechsler, et al.
Diabetes Care|April 26, 2022
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical TrialsKatherine R Tuttle, Adeera Levin, Masaomi Nangaku, et al.
Pageof 79

Showing results (401-410 of 785) with videos related to

Sort By:
Pageof 79
Kidney International Reports|August 4, 2023
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)William G Herrington, Charlie Harper, Natalie Staplin, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|July 2, 2011
Tei index in fabry diseaseMarkus Niemann, Frank Breunig, Meinrad Beer, et al.
Advances in Therapy|May 28, 2025
Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative ReviewChristoph Wanner, Ming-Hui Zhao, Alpesh N Amin, et al.
Open Heart|July 19, 2018
Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry diseaseDan Liu, Daniel Oder, Tim Salinger, et al.
Molecular Genetics and Metabolism|May 23, 2018
The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of expertsMarco Spada, Ralf Baron, Perry M Elliott, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 3, 2016
Performance of hemodialysis with novel medium cut-off dialyzersAlexander H Kirsch, Raphael Lyko, Lars-Göran Nilsson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 9, 2021
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME TrialOdette S Reifsnider, Anuraag R Kansal, Christoph Wanner, et al.
Eclinicalmedicine|January 10, 2022
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomesPiero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 16, 2011
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysisWinfried März, Bernd Genser, Christiane Drechsler, et al.
Diabetes Care|April 26, 2022
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical TrialsKatherine R Tuttle, Adeera Levin, Masaomi Nangaku, et al.
Pageof 79